Vasoactive Intestinal Peptide (VIP) Explained
Gut Peptide Hormones
28 amino acids
VIP is a 28-amino-acid neuropeptide that was first isolated from porcine duodenum in 1970 and has since been found throughout the nervous and immune systems.
Said, Ann NY Acad Sci, 2008
Said, Ann NY Acad Sci, 2008
View as imageWhen Sami Said and Viktor Mutt isolated a peptide from porcine duodenum in 1970, they named it for its ability to dilate blood vessels: vasoactive intestinal peptide, or VIP.[3] That name turned out to be misleadingly narrow. Over the following decades, researchers discovered that VIP does far more than dilate vessels. It regulates gut motility, controls secretion of digestive fluids, maintains the intestinal epithelial barrier, modulates immune responses, and functions as a neurotransmitter in the central and peripheral nervous systems. VIP is one of the most widely distributed neuropeptides in the body, expressed in neurons throughout the gut, brain, lungs, and immune tissue.[1] Among the many peptide hormones your gut produces, VIP stands out for the sheer breadth of its biological roles, spanning from the stomach's cleaning waves regulated by motilin to the immune tolerance mechanisms that prevent your body from attacking its own intestinal bacteria.
Key Takeaways
- VIP is a 28-amino-acid neuropeptide that signals through two G-protein coupled receptors (VPAC1 and VPAC2), both of which activate cAMP-dependent pathways in target cells (Said, 2008)
- In the gut, VIP relaxes smooth muscle, stimulates water and electrolyte secretion, inhibits gastric acid production, and promotes pancreatic enzyme release (Gonzalez-Rey and Delgado, 2007)
- VIP is one of the most potent endogenous anti-inflammatory peptides: it suppresses Th1 and Th17 responses, promotes regulatory T cell differentiation, and inhibits pro-inflammatory cytokine production through VPAC2 activation (Gutierrez-Canas et al., 2008)
- VIP-deficient mice develop spontaneous intestinal inflammation, disrupted gut microbiota, and impaired immune tolerance, demonstrating VIP's essential role in maintaining gut homeostasis (Abad et al., 2015)
- Therapeutic applications under investigation include inflammatory bowel disease, rheumatoid arthritis, sepsis, and pulmonary hypertension, though clinical translation remains early-stage
- VIP plasma levels are elevated during active inflammatory bowel disease, suggesting a compensatory anti-inflammatory response and potential biomarker utility (Delgado and Ganea, 2013)
VIP structure and receptor biology
VIP is a linear 28-amino-acid peptide belonging to the secretin/glucagon superfamily, which also includes secretin, glucagon, GLP-1, GLP-2, and PACAP (pituitary adenylate cyclase-activating polypeptide). VIP shares 68% sequence homology with PACAP, and the two peptides have overlapping but distinct biological functions. This family relationship explains why VIP and PACAP sometimes activate the same receptors, creating redundancy in some signaling pathways and making selective pharmacological targeting of VIP signaling a persistent challenge.[3]
VIP signals through two primary receptors, both members of the class B G-protein coupled receptor family:
VPAC1 is widely distributed, expressed in the gut, lungs, liver, brain, and on T lymphocytes. VPAC1 activation primarily drives gastrointestinal effects: smooth muscle relaxation, secretion stimulation, and vasodilation.[1]
VPAC2 is expressed in the brain (especially the suprachiasmatic nucleus, which controls circadian rhythms), smooth muscle, and immune cells. VPAC2 activation is the primary mediator of VIP's immunomodulatory effects, suppressing pro-inflammatory T cell responses and promoting immune tolerance.[4]
Both receptors signal through adenylate cyclase, raising intracellular cAMP levels. The downstream effects depend on cell type: in smooth muscle cells, cAMP causes relaxation; in immune cells, it suppresses inflammatory gene transcription; in epithelial cells, it drives chloride and water secretion into the intestinal lumen.[3]
VIP in the gut: motility, secretion, and barrier function
VIP is the principal inhibitory neurotransmitter in the enteric nervous system, the network of neurons embedded in the gut wall that controls digestive function independently of the brain. VIP-releasing neurons are found throughout the gastrointestinal tract, from the esophagus to the colon.[1]
Smooth muscle relaxation. VIP relaxes gut smooth muscle, contributing to the receptive relaxation of the stomach (allowing it to expand when food arrives), the relaxation phase of peristaltic contractions, and the relaxation of sphincters (lower esophageal sphincter, pyloric sphincter, sphincter of Oddi). This makes VIP essential for coordinated intestinal motility.[1]
Secretion. VIP stimulates water and electrolyte secretion from intestinal epithelial cells and stimulates pancreatic bicarbonate and enzyme secretion. It also promotes hepatic bile flow. These secretory effects facilitate digestion and maintain the luminal environment needed for nutrient absorption.[3]
Gastric acid inhibition. VIP inhibits gastric acid secretion, acting as a counterbalance to acid-stimulating peptides like gastrin. This effect is mediated through VPAC1 receptors on parietal cells and through indirect effects on histamine-releasing enterochromaffin-like cells. The balance between VIP (inhibitory) and gastrin (stimulatory) helps maintain appropriate acid levels for digestion without causing acid-mediated tissue damage.
Epithelial barrier maintenance. VIP helps maintain the integrity of the intestinal epithelial barrier, the single-cell layer that separates luminal contents (including bacteria and food antigens) from the immune-rich tissue beneath. Disruption of this barrier is a central event in inflammatory bowel disease, and VIP's barrier-protective effects may be part of the gut's defense against inflammation.[7]
VIP as an immune regulator
VIP's immunomodulatory properties are among its most studied and therapeutically relevant functions. The peptide is a potent endogenous anti-inflammatory agent that acts on virtually every arm of the immune system.[4]
T cell polarization. VIP shifts the T helper cell balance away from pro-inflammatory Th1 and Th17 responses and toward anti-inflammatory Th2 and regulatory T cell (Treg) responses. This is primarily mediated through VPAC2 receptors on T cells. The result is reduced production of IFN-gamma, TNF-alpha, and IL-17, and increased production of IL-10 and TGF-beta.[4]
Macrophage inhibition. VIP suppresses the production of pro-inflammatory cytokines and reactive oxygen species by activated macrophages. It inhibits the NF-kB signaling pathway in macrophages, reducing transcription of inflammatory genes including TNF-alpha, IL-6, and IL-12.[1]
Dendritic cell tolerization. VIP promotes the generation of tolerogenic dendritic cells, antigen-presenting cells that suppress rather than activate immune responses. These tolerogenic dendritic cells promote Treg differentiation and contribute to immune tolerance.[5]
Innate immunity. VIP modulates Toll-like receptor (TLR) signaling in innate immune cells, dampening the inflammatory response to bacterial components while maintaining the ability to clear infections. This is particularly relevant in the gut, where the immune system must tolerate commensal bacteria while remaining vigilant against pathogens.[4]
Gonzalez-Rey and Delgado characterized these combined effects as making VIP one of the body's master regulators of immune homeostasis, integrating signals across innate and adaptive immunity to maintain the balance between protective inflammation and tissue-damaging overactivation.[1]
What happens when VIP is absent
The most direct evidence for VIP's importance comes from VIP-knockout mouse studies. Abad and colleagues (2015) created VIP-deficient mice and observed a range of gastrointestinal and immunological abnormalities.[7]
VIP-deficient mice developed spontaneous intestinal inflammation resembling inflammatory bowel disease. Their gut microbiota composition was altered, with shifts in bacterial community structure that paralleled changes seen in human IBD. The intestinal epithelial barrier was compromised, allowing increased bacterial translocation across the gut wall. Immune tolerance to commensal bacteria was impaired, with increased Th1 and Th17 responses in the gut-associated lymphoid tissue.[7]
These findings demonstrate that VIP is not merely an anti-inflammatory molecule that can be added to calm inflammation. It is an essential component of the gut's homeostatic machinery, without which the balance between immune tolerance and immune activation breaks down. The spontaneous inflammation in VIP-knockout mice suggests that endogenous VIP production is continuously required to maintain gut peace.
VIP beyond the gut: brain, lungs, and circadian rhythm
VIP's distribution extends well beyond the gastrointestinal tract. It is one of the most abundant neuropeptides in the central nervous system, where it functions as both a neurotransmitter and a neuromodulator.[5]
In the brain, VIP-expressing neurons in the suprachiasmatic nucleus are critical for circadian rhythm synchronization. VIP signaling through VPAC2 coordinates the firing patterns of clock neurons, maintaining the 24-hour cycle that governs sleep-wake behavior, hormone secretion, and metabolism. Disrupted VIP signaling has been linked to circadian rhythm disorders and sleep disturbances.[5]
In the lungs, VIP is a potent bronchodilator and vasodilator. Inhaled VIP has been tested in patients with pulmonary arterial hypertension, a condition characterized by excessive vasoconstriction in the pulmonary circulation. Early clinical studies showed improvements in pulmonary hemodynamics, though the evidence base remains limited.[3]
VIP also has neuroprotective properties, promoting neuronal survival under stress conditions and modulating synaptic plasticity. In hippocampal neurons, VIP enhances synaptic transmission and long-term potentiation, processes central to memory formation. VIP-expressing interneurons in the cortex play a role in attention and sensory processing by disinhibiting principal neurons through a specialized inhibition-of-inhibition circuit. These neural functions are being explored in the context of neurodegenerative diseases and cognitive disorders, though therapeutic applications targeting brain VIP signaling are early-stage.[5]
Therapeutic potential and clinical challenges
The breadth of VIP's anti-inflammatory and immunoregulatory effects has made it an attractive therapeutic candidate for multiple conditions.[6]
Inflammatory bowel disease. VIP's ability to suppress Th1/Th17 responses, promote Tregs, and maintain epithelial barrier integrity makes it theoretically well-suited for treating Crohn's disease and ulcerative colitis. Elevated VIP plasma levels during active IBD suggest the body increases VIP production as a compensatory anti-inflammatory response.[2] The question is whether exogenous VIP can augment this natural defense.
Rheumatoid arthritis. VIP suppresses the Th1-driven inflammation characteristic of rheumatoid arthritis in animal models, reducing joint destruction and inflammatory cell infiltration. Souza-Moreira and colleagues reviewed the evidence supporting VIP as a therapeutic agent for autoimmune conditions, noting consistent benefit across multiple animal models of autoimmunity.[6]
Sepsis. VIP's ability to dampen excessive inflammatory responses while preserving antimicrobial function has attracted interest in sepsis, where uncontrolled systemic inflammation is the primary driver of organ damage and death. Animal models of sepsis have shown that VIP administration reduces mortality, decreases pro-inflammatory cytokine levels, and preserves organ function. The challenge in sepsis is achieving rapid enough drug delivery, since the therapeutic window is narrow and VIP's half-life is very short.[1]
Clinical translation faces a persistent challenge: VIP has a plasma half-life of approximately 1-2 minutes, rapidly degraded by peptidases in the blood. Delivering therapeutically effective concentrations to target tissues requires either continuous infusion, local delivery (inhaled for pulmonary hypertension), or development of protease-resistant VIP analogs. Fan and colleagues (2025) reviewed recent advances in VIP analog design and delivery strategies aimed at overcoming this pharmacokinetic barrier.[8]
The development of long-acting VIP analogs, VIP-loaded nanoparticles, and targeted delivery systems represents the current frontier. Whether these approaches can translate VIP's consistent preclinical efficacy into proven human therapy remains an open question, but the biological rationale is supported by decades of mechanistic research across multiple organ systems.
The Bottom Line
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide with functions spanning gut motility, secretion, immune regulation, vasodilation, and circadian rhythm control. In the gut, VIP relaxes smooth muscle, stimulates secretion, and maintains epithelial barrier integrity. In the immune system, it suppresses inflammatory Th1/Th17 responses and promotes regulatory T cell differentiation, primarily through VPAC2 receptors. VIP-knockout mice develop spontaneous intestinal inflammation, confirming VIP as essential for gut immune homeostasis. Therapeutic applications for IBD, autoimmune disease, and pulmonary hypertension are under investigation, though VIP's very short plasma half-life remains the primary obstacle to clinical development.